Start Low — The First Dose in a Cannabis-Naive Patient
Individual response to THC varies widely, so treatment begins at the smallest plausible dose.
- 1–2.5 mg: Typical starting dose (THC, cannabis-naive)
- CB1: Endocannabinoid receptor (primary psychoactive target)
- High: Inter-patient variability (metabolism, tolerance differ)
- Elevated: Naive ED-visit risk (without slow titration)
Why start this low
Placeholder: narrow therapeutic index makes small starting doses safer.
Patient factors considered
Placeholder: age, weight, prior use, and comorbidities shape the starting dose.
Setting expectations
Placeholder: patients are told effects build slowly across visits, not one dose.
Assessing Effect — Route-Specific Onset Timing
Adequate observation time must pass before judging whether a dose worked.
- 2–10 min: Inhaled onset (peak ~30 min)
- 30–120 min: Edible onset (peak 2–4 hours)
- 6–8 hr: Edible duration (longer than inhaled)
- Re-dosing early: Common error (before onset completes)
Inhaled route timing
Placeholder: fast onset allows quick, incremental effect checks.
Edible route timing
Placeholder: delayed onset risks impatient, stacked re-dosing.
Why waiting matters
Placeholder: judging too early causes accidental overdose later.
Gradual Dose Increase When Relief Is Inadequate
Small stepwise increases are made only when relief is insufficient and no side effects appeared.
- 1–2.5 mg: Typical step size (per increase)
- Days: Minimum interval (between increases)
- No relief AND no effects: Rule (both required to raise dose)
- Slow convergence: Goal (toward effective dose)
Step-wise increase logic
Placeholder: raise dose only in small, spaced increments.
Monitoring between steps
Placeholder: patient logs relief and any psychoactive symptoms.
When to pause increases
Placeholder: any unwanted effect halts further dose increases.
Careful Titration Toward the Therapeutic Window
Titration continues while watching the gap between relief and unwanted psychoactive effects.
- Narrow: Therapeutic window (relief vs. side effects)
- Anxiety: Key side effect (most reported at high dose)
- Weekly: Monitoring cadence (typical follow-up)
- Bidirectional: Adjustment direction (up or down as needed)
Balancing two curves
Placeholder: relief and side-effect curves are tracked together.
Signs of overshoot
Placeholder: anxiety, sedation, or impairment signal reducing dose.
Route switching
Placeholder: some patients change route to ease titration control.
Individualized Optimal Dose Within the Therapeutic Window
Titration ends once a stable dose delivers relief without excessive psychoactive effect.
- Optimal dose found: Outcome (individualized, stable)
- Edible overdose: Common ED cause (delayed-onset re-dosing)
- No relief: Under-dosing risk (patient discontinues therapy)
- Excess psychoactivity: Over-dosing risk (anxiety, impairment, ED visits)
What success looks like
Placeholder: consistent relief at the lowest effective, tolerated dose.
Avoiding both failure modes
Placeholder: neither under-dosed nor over-dosed extremes serve the patient.
Maintaining the window
Placeholder: periodic reassessment keeps dosing within the sweet spot.
Placeholder highlight: edible overdoses are a leading avoidable ED visit cause.